生物医药是新一轮科技革命和竞争的焦点赛道之一，也是国家长期支持的新质生产力行业。南京聚焦以科技创新引领新质生产力发展，自成立市生物医药 产业攻坚办(以下简称"攻坚办")以来，积极对接行业重点企业，通过顶层设计将政策、人才等资源向生物医药产业倾斜，全链条赋能产业高质量发展。 2025年，南京共有三款Ⅰ类创新药获批，排名全国城市前列。 12月23日，记者先后走进南京世和基因生物技术股份有限公司、南京征祥医药有限公司、卡秋(江苏)生物科技有限公司探访，深切感受到，在这场关乎人 类健康的科技角逐中，南京企业正凭借一系列突破性成果脱颖而出，全市生物医药产业尽显"生"机盎然、"新"潮澎湃的发展态势。 全生命周期护航，首个、首批"群星闪耀" "肿瘤，不应是一场'宣判'。"步入世和基因展厅，这句铿锵之言扑面而来，默默彰显着企业的使命与抱负。在其斜对角的产品展示柜上，白色包装盒的"世 和一号"看似普通，却意义重大——它在今年8月以实体瘤全适应证获美国药监局(FDA)批准，成为全球首个且唯一中美欧三证高通量测序大Panel试剂盒， 实现了"一次检测，全球通认"。这一"大满贯"成果，不仅彰显企业强劲的创新实力，也体现出南京生物医药 ...

□ 本报记者 王梦然 12月18日，海南自由贸易港全岛封关运作正式启动。当天上午，南京江北新区生物医药谷会议室内，江 苏鼎泰药物研究(集团)股份有限公司工作人员正通过视频系统与海南文昌基地的团队连线。屏幕上实时 显示着实验猴舍内的画面，食蟹猴灵活地攀爬、跳跃，表现出高度的活力。"我们早在3年前就布局海 南，封关后，我们的实验动物进出口将享受更多便利。"工作人员指着屏幕说，今后全球研发合作通道 将更加顺畅。 业内认为，海南封关为江苏制造提供了一个"境内关外"的战略跳板，江苏企业可以依托海南，实现"全 球采购、国际加工、离岸销售"的新型商业模式，这不仅仅是成本节约，更是全球资源配置能力的跃 升。从制造业的"借船出海"，到生物医药的"研发+转化"，再到数字经济的"规则共建"……江苏将凭借 雄厚的产业基础和创新实力，成为这场改革中活跃的参与者与受益者。 巧借政策跳板，便利制造出海 鼎泰药研（集团）是这一模式的先行者。早在2022年，这家总部位于南京江北新区的CRO企业就开始 在海南文昌布局。"我们用时一年，建成了海南亚灵生物科技有限公司，并持续引进高质种群，公司拥 有国内规模最大的非人灵长类动物(NHP)研究核心年轻 ...

Core Insights - Nanjing Biomedicine Valley has introduced over 50 innovative products and technologies that are first in the world or country, highlighting its role as a key player in the biomedicine industry [1] - The region is focusing on precision medicine and niche areas such as brain science and gene therapy, aiming to establish a comprehensive innovation ecosystem [2][3] - Two new class 1 drugs have been approved this year, marking a significant achievement for the Nanjing Biomedicine Valley [3][4] Industry Overview - The global biomedicine industry is accelerating towards precision diagnosis and treatment, with Nanjing Biomedicine Valley positioning itself in niche markets [2] - The region has established a full industrial chain in gene and cell therapy, including gene testing, diagnostics, and CAR-T cell therapy [3] - The Nanjing Biomedicine Valley has attracted over 1,300 companies, with 7 companies successfully listed and 6 class 1 drugs approved [5] Innovation and Development - The Nanjing Biomedicine Valley is enhancing its innovation capabilities by collaborating with universities and establishing technology transfer centers [6] - A total of 84 billion yuan fund support plan has been launched to facilitate the transformation of scientific achievements from universities [6] - The region is focusing on building a robust innovation ecosystem that integrates innovation chains, industry chains, capital chains, and talent chains [7] Recent Achievements - The approval of two class 1 drugs, Enze Shou and Ji Ke Shu, represents a milestone for the biomedicine valley, with the former being the first targeted drug for platinum-resistant ovarian cancer in China [3][4] - The establishment of the Jiangsu Brain Intelligence Technology Innovation Center aims to make breakthroughs in brain science over the next five years [2] - The Nanjing Biomedicine Valley has successfully facilitated the listing of companies and the approval of innovative drugs, showcasing its supportive environment for biomedicine enterprises [5][6]